Vietnam Veterans with Diabetes, Diabetes, Vietnam, Veterans


New Drug

Posted by Randall W Brown on March 10, 2015 at 10:30 AM

In late February, Sanofi announced FDA approval of its once-daily, long-acting basal insulin Toujeo. Toujeo is the same type of basal insulin (glargine) as Sanofi’s blockbuster Lantus, but a stronger version. In Toujeo, each milliliter of liquid carries 300 units of insulin (“U300”), whereas Lantus only carries 100 units of insulin per milliliter (“U100”). Sanofi hopes to bring Toujeo to the market in the next month – a very quick turnaround! It has also been tentatively approved in Europe, with a final decision expected in the coming months. Pricing and insurance information are not available at this time. Toujeo will be sold in a new SoloStar pen that will carry 450 units, 50% more than the 300-unit Lantus pen – a major improvement for the many people who require larger doses of insulin. In Sanofi’s New Medicines Seminar in November, we learned that Toujeo will come with a substantial patient support program, using multiple forms of contact (online, phone, in person) to help patients transition onto the new insulin. Toujeo’s approval was based on the results of the EDITION clinical trials, which evaluated its efficacy and safety compared to Lantus in over 3,500 adults with type 1 and type 2 diabetes. In short, Toujeo was found to be just as safe and effective as Lantus. In the trials, Toujeo was slightly more effective at lowering A1c than Lantus, had no significant difference in weight gain, and had mixed results for potential hypoglycemia benefits (some trials showed a benefit, others did not). We wonder if the real-world experience with Toujeo will show larger benefits on hypoglycemia. Full information on the drug’s dosing and side effects can be found here. Toujeo’s approval clears the path for a combination with the GLP-1 agonist lixisenatide. Novo Nordisk’s Xultophy (a combination of Victoza and Tresiba) is the only currently approved GLP-1 agonist/ basal insulin combination drug, having received approval in Europe last September. While Toujeo could be a valuable option for many by itself, we most look forward to its combination with lixisenatide. –ER/AJW - See more at:

Categories: None

Post a Comment


Oops, you forgot something.


The words you entered did not match the given text. Please try again.

Already a member? Sign In